Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Decreases By 86.9%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 56,379 shares, a decrease of 86.9% from the July 15th total of 429,660 shares. Currently, 9.0% of the shares of the company are short sold. Based on an average daily trading volume, of 736,949 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Several research analysts recently issued reports on SHPH shares. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Shuttle Pharmaceuticals presently has an average rating of “Sell”.

Shuttle Pharmaceuticals Trading Up 8.3%

NASDAQ:SHPH traded up $0.35 during trading hours on Thursday, hitting $4.58. The company’s stock had a trading volume of 93,709 shares, compared to its average volume of 555,389. Shuttle Pharmaceuticals has a 52-week low of $2.58 and a 52-week high of $55.90. The business’s 50-day moving average is $3.69 and its two-hundred day moving average is $7.73.

Insider Activity at Shuttle Pharmaceuticals

In other news, major shareholder Financial Lp Hrt bought 8,266 shares of Shuttle Pharmaceuticals stock in a transaction dated Thursday, July 9th. The stock was bought at an average price of $3.38 per share, for a total transaction of $27,939.08. Following the purchase, the insider owned 60,540 shares of the company’s stock, valued at approximately $204,625.20. The trade was a 15.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have acquired 53,398 shares of company stock valued at $181,764 and have sold 38,133 shares valued at $132,128. Company insiders own 1.31% of the company’s stock.

Institutional Trading of Shuttle Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals during the third quarter worth about $357,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter valued at about $124,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals in the fourth quarter valued at about $37,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals during the 4th quarter valued at approximately $26,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .